NCT01399125View on ClinicalTrials.gov

A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

501

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Alzheimer's Disease
Interventions
DRUG

Rivastigmine Patch

Once-daily target patch size 10 cm²

DRUG

Rivastigmine Capsules

Twice-daily target dose of 6 mg oral capsule

DRUG

Placebo to Rivastigmine patch

Matching placebo to Rivastigmine patch

DRUG

Placebo to Rivastigmine capsules

matching Placebo to Rivastigmine capsules

Trial Locations (16)

100028

Novartis Investigative Site, Beijing

100730

Novartis Investigative Site, Beijing

130021

Novartis Investigative Site, Changchun

200003

Novartis Investigative Site, Shanghai

200025

Novartis Investigative Site, Shanghai

200040

Novartis Investigative Site, Shanghai

200080

Novartis Investigative Site, Shanghai

200127

Novartis Investigative Site, Shanghai

210029

Novartis Investigative Site, Nanjing

215004

Novartis Investigative Site, Suzhou

310009

Novartis Investigative Site, Hangzhou

430022

Novartis Investigative Site, Wuhan

430030

Novartis Investigative Site, Wuhan

610041

Novartis Investigative Site, Chengdu

710032

Novartis Investigative Site, Xi’an

Unknown

Novartis Investigative Site, Fuzhou

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY